Matrix Metallopeptidase 14: A Candidate Prognostic Biomarker for Diffuse Large B-Cell Lymphoma

Chengliang Yin; Junyan Zhang; Ming Shen; Zhenyang Gu; Yan Li; Wanguo Xue; Jinlong Shi; Wenrong Huang

doi:10.3389/fonc.2020.01520

Matrix Metallopeptidase 14: A Candidate Prognostic Biomarker for Diffuse Large B-Cell Lymphoma

Front Oncol. 2020 Aug 20:10:1520. doi: 10.3389/fonc.2020.01520. eCollection 2020.

Authors

Chengliang Yin^{1

2}, Junyan Zhang^{1

2}, Ming Shen³, Zhenyang Gu⁴, Yan Li⁴, Wanguo Xue^{1

2}, Jinlong Shi^{1

2

5}, Wenrong Huang⁴

Affiliations

¹ National Engineering Laboratory for Medical Big Data Application Technology, Chinese PLA General Hospital, Beijing, China.
² Medical Big Data Research Center, Chinese PLA General Hospital, Beijing, China.
³ Translational Medicine Laboratory, Chinese PLA General Hospital, Beijing, China.
⁴ Department of Hematology, Chinese PLA General Hospital, Beijing, China.
⁵ Department of Biomedical Engineering, Chinese PLA General Hospital, Beijing, China.

Abstract

Background: Matrix metallopeptidase 14 (MMP14) is an important gene in the regulation of T-cell function. However, the correlation between MMP14 expression, prognosis, and immune cell infiltration in diffuse large B-cell lymphoma (DLBCL) remains unclear.

Methods: We investigated the influence of MMP14 on clinical prognosis using data obtained from three Gene Expression Omnibus (GEO) database sets (GSE98588, GSE10846, and GSE4475). The expression of MMP14 was analyzed using the Gene Expression Profiling Interactive Analysis (GEPIA). The correlation between MMP14 and immune cell infiltration was investigated using the Cell-type Identification By Estimating Relative Subsets Of RNA Transcripts (CIBERSORT) and Tumor Immune Estimation Resource (TIMER) tools. In addition, the correlation between MMP14 expression and immune gene markers was analyzed by TIMER and GEPIA.

Results: MMP14 expression positively correlated with favorable progression-free survival (PFS; GSE98588, P = 0.02) and overall survival (OS; GSE98588, P = 0.003; GSE10846, P = 5.517e-05; and GSE4475, P = 9.85e-04). Moreover, MMP14 expression was higher in DLBCL tumors than in normal tissues. Regarding clinical characteristics, high MMP14 expression was found to be correlated with race. MMP14 expression was also correlated with immune cell infiltration and had a remarkable correlation with various immune marker sets. It was found that M0 macrophages were the immune cells most related to survival, decreasing with the increase in Ann Arbor clinical stage. The results especially showed that MMP14 was a prognostic biomarker and related to the macrophages M0.

Conclusion: The results suggest that MMP14 is a novel prognostic molecular marker for DLBCL and is related to the immune cell infiltration, especially related to the macrophages M0. Our study provides insights for understanding the potential roles of MMP14 in tumor immunology and its suitability as a prognosis biomarker in DLBCL.

Keywords: biomarker; diffuse large B-cell lymphoma; immune cell infiltration; matrix metallopeptidase 14; prognosis.